BriaCell Announces Proposed Effective Date of Share Consolidation
BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation to maintain Nasdaq listing compliance. The consolidation is expected to take effect on August 25, 2025, with post-consolidation trading beginning around August 26, 2025, subject to TSX and Nasdaq approval.
Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of ½ or greater to one whole share, while smaller fractions will be cancelled. The company's convertible securities will be proportionally adjusted, and trading symbols will remain unchanged on both exchanges.
BriaCell Therapeutics (NASDAQ: BCTX), una società biotecnologica in fase clinica, ha annunciato una consolidazione azionaria 1-per-10 per mantenere la conformità alla quotazione Nasdaq. La consolidazione dovrebbe entrare in vigore il 25 agosto 2025, con l'inizio delle negoziazioni post-consolidamento previsto intorno al 26 agosto 2025, subordinatamente all'approvazione di TSX e Nasdaq.
Secondo i termini della consolidazione, gli azionisti riceveranno una nuova azione per ogni dieci azioni possedute. Le azioni frazionarie saranno gestite arrotondando per eccesso le frazioni pari o superiori a ½ a un'azione intera, mentre le frazioni inferiori saranno annullate. I titoli convertibili della società saranno adeguati proporzionalmente e i simboli di negoziazione rimarranno invariati su entrambe le borse.
BriaCell Therapeutics (NASDAQ: BCTX), una empresa biotecnológica en etapa clínica, ha anunciado una consolidación de acciones 1 por 10 para mantener el cumplimiento de la cotización en Nasdaq. Se espera que la consolidación entre en vigor el 25 de agosto de 2025, con el inicio de la negociación post-consolidación alrededor del 26 de agosto de 2025, sujeto a la aprobación de TSX y Nasdaq.
Bajo los términos de la consolidación, los accionistas recibirán una acción nueva por cada diez acciones existentes. Las acciones fraccionarias se manejarán redondeando hacia arriba las fracciones de ½ o más a una acción completa, mientras que las fracciones menores se cancelarán. Los valores convertibles de la compañía se ajustarán proporcionalmente y los símbolos de negociación permanecerán sin cambios en ambas bolsas.
BriaCell Therapeutics (NASDAQ: BCTX)는 임상 단계의 바이오테크 기업으로, 나스닥 상장 규정 준수를 위해 1주당 10주 합병을 발표했습니다. 합병은 2025년 8월 25일에 시행될 예정이며, 합병 후 거래는 TSX와 나스닥의 승인에 따라 2025년 8월 26일경 시작될 예정입니다.
합병 조건에 따라 주주들은 기존 10주당 1주의 신주를 받게 됩니다. ½주 이상인 소수 주식은 1주로 반올림 처리되며, 그보다 작은 소수 주식은 소멸됩니다. 회사의 전환증권도 비례적으로 조정되며, 두 거래소 모두에서 거래 심볼은 변경되지 않습니다.
BriaCell Therapeutics (NASDAQ : BCTX), une société biotechnologique en phase clinique, a annoncé une consolidation d’actions au ratio de 1 pour 10 afin de maintenir sa conformité avec les exigences de cotation du Nasdaq. La consolidation devrait entrer en vigueur le 25 août 2025, avec un début des échanges post-consolidation aux alentours du 26 août 2025, sous réserve de l’approbation de la TSX et du Nasdaq.
Selon les modalités de la consolidation, les actionnaires recevront une nouvelle action pour dix actions existantes. Les fractions d’actions seront arrondies à l’unité supérieure si elles sont égales ou supérieures à ½, les fractions inférieures seront annulées. Les titres convertibles de la société seront ajustés proportionnellement et les symboles de négociation resteront inchangés sur les deux places boursières.
BriaCell Therapeutics (NASDAQ: BCTX), ein Biotechnologieunternehmen in der klinischen Phase, hat eine Aktienzusammenlegung im Verhältnis 1 zu 10 angekündigt, um die Nasdaq-Listenanforderungen einzuhalten. Die Zusammenlegung soll am 25. August 2025 wirksam werden, wobei der Handel nach der Zusammenlegung voraussichtlich ab dem 26. August 2025 beginnt, vorbehaltlich der Genehmigung durch TSX und Nasdaq.
Gemäß den Bedingungen der Zusammenlegung erhalten Aktionäre für jeweils zehn bestehende Aktien eine neue Aktie. Bruchstücke von Aktien werden aufgerundet, wenn sie ½ oder mehr betragen, andernfalls entfallen sie. Die wandelbaren Wertpapiere des Unternehmens werden anteilig angepasst, und die Handelssymbole bleiben an beiden Börsen unverändert.
- Share consolidation helps maintain Nasdaq listing compliance
- Clear 1:10 consolidation ratio provides certainty to shareholders
- Rounding up of fractional shares ≥ ½ benefits small shareholders
- Significant reduction in total outstanding shares may impact trading liquidity
- Shareholders with less than ½ share post-consolidation will lose their holdings
Insights
BriaCell's 1:10 share consolidation aims to maintain Nasdaq compliance, effectively reducing share count while preserving proportional ownership.
BriaCell Therapeutics is implementing a 1-for-10 share consolidation to ensure continued compliance with Nasdaq listing requirements. This reverse split, expected to take effect on August 25, 2025, will proportionally reduce the number of outstanding shares while maintaining each shareholder's relative ownership percentage.
This type of corporate action typically occurs when a company needs to boost its share price to meet exchange minimum price requirements. While the consolidation changes the share count and price, it doesn't fundamentally alter the company's market capitalization or intrinsic value.
For shareholders, this means each position will be adjusted accordingly - every 10 shares currently owned will convert to 1 share post-consolidation. The post-consolidation shares will continue trading under the same symbols (BCT on TSX and BCTX on Nasdaq). Fractional shares will be handled with a standard rounding mechanism - fractions below 0.5 will be canceled while those 0.5 or above will be rounded up to a whole share.
Any convertible securities (options, warrants, etc.) will also see their exercise prices and issuable shares adjusted proportionally. Registered shareholders will receive instructions from Computershare for exchanging their shares, while beneficial holders who own shares through brokerages need not take action as their positions will adjust automatically.
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
The Consolidation is subject to approval by the Toronto Stock Exchange (the “TSX”) and Nasdaq and is expected to become effective on August 25, 2025 (the “Effective Date”), with the post-Consolidation Common Shares commencing trading on the TSX and the Nasdaq at market open on or about August 26, 2025, subject to final confirmation from the TSX and the Nasdaq. No fractional Common Shares will be issued in connection with the Consolidation. Any fractional Common Shares remaining after the Consolidation that are less than ½ of a Common Share will be cancelled, and each fractional Common Share that is at least ½ of a Common Share will be rounded up to one whole Common Share. The Company does not intend to round up fractional shares at the beneficial level and will instead round any such fractional shares up at the participant level. The exercise or conversion price and/or the number of Common Shares issuable under any of the Company’s outstanding convertible securities will be proportionately adjusted in connection with the Consolidation.
It is anticipated that upon completion of the Consolidation, the post-Consolidation Common Shares will continue to trade on the TSX under the symbol “BCT” and on the Nasdaq under the symbol “BCTX”.
Shareholders of record as of the Effective Date will receive a letter of transmittal from Computershare Investor Services Inc., the transfer agent for the Common Shares, providing instructions for the exchange of their Common Shares as soon as practicable following the Effective Date.
Registered shareholders may also obtain a copy of the letter of transmittal by accessing the Company’s SEDAR+ profile at www.sedarplus.ca. Until surrendered, each share certificate or direct registration system statement representing pre-Consolidation Common Shares will represent the number of whole post-Consolidation Common Shares to which the holder is entitled as a result of the Consolidation. No action is required by beneficial holders to receive post-Consolidation Common Shares in connection with the Consolidation. Beneficial holders who hold their Common Shares through intermediaries (e.g., a broker, bank, trust company investment dealer or other financial institution) and who have questions regarding how the Consolidation will be processed should contact their intermediaries with respect to the Consolidation.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements, such as those are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
When will BriaCell's (BCTX) share consolidation take effect?
What is the ratio for BriaCell's (BCTX) share consolidation in 2025?
How will BriaCell (BCTX) handle fractional shares in the 2025 consolidation?
Why is BriaCell (BCTX) implementing a share consolidation in 2025?
Will BriaCell's stock symbol change after the 2025 consolidation?
